Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes

Table 2 Demographic and clinical characteristics of the cohort

	Non-multiple sclerosis (n = 80)	Multiple sclerosis (n = 77)
Age at sampling—years—mean (SD)	33.2 (10.2)	41.9 (12.4)
Gender—count (%)	Female 72 (90%) Male 8 (10%)	Female 46 (60%) Male 31 (40%)
Diagnosis—count	IIH 59 Primary headache 10 Sensory disturbance 3 FND 3 Epilepsy 2 SPS 1 Arthritis 1 Viral meningitis 1	RRMS 57 SPMS 10 PPMS 10
Baseline EDSS—median (range)		2.5 (1.0–7.5)
Follow-up duration—mean (SD)	–	7.9 (3.5) years
Disease modifying therapy (ever exposed)—count	–	Yes 46* (High efficacy 27) No 31
Relapse(s) experienced during follow-up—count (%)	–	46⁺ (60%)
Reached EDSS 6—count (%)	–	23 (30%)
Oligoclonal bands in CSF	–	Unpaired 53 (69%) Paired 9 (12%) Negative 15 (19%)

IIH idiopathic intracranial hypertension, FND functional neurological disorder, SPS stiff person syndrome, RRMS relapsing–remitting multiple sclerosis, S/PPMS secondary/primary progressive multiple sclerosis. High efficacy disease modifying therapy: monoclonal antibody or cladribine treatment; *Only 2 people with multiple sclerosis were exposed to disease modifying therapy at the time of sampling. ⁺ 36 experienced their relapse prior to commencing disease modifying therapy (prior to censor)

ISSN: 1742-2094